Video Latest - ecancer

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

Dr Olivier Casasnovas - CHU de Dijon, Dijon, France

15 Jun 2018

Update on bb2121 for relapsed myeloma

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

15 Jun 2018

Results from the phase I ICONIC trial

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

4 Jun 2018

Daratumumab in combination with carfilzomib and dexamethasone for relapsed multiple myeloma

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

4 Jun 2018

A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

2 Jun 2018

Immunotherapy trials and hyperprogressive disease

Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

2 Jun 2018

Linking Lynch Syndrome and microsatellite instability in tumours

Dr Zsofia Kinga Stadler - Memorial Sloan Kettering Cancer Center, New York, USA

2 Jun 2018

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Denver, USA

2 Jun 2018

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Denver, USA

2 Jun 2018

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer

21 May 2018

Identifying drivers of resistance in childhood brain tumours

Dr Pratiti Bandopadhayay - Dana-Farber Cancer Institute, Boston, USA

11 May 2018

Incorporating patient perspective during myeloma treatment

Dr Karthik Ramasamy - Oxford University Hospital, Oxford, UK

2 May 2018

Video